FDA Panel Recommends Stricter Regulatory Standards For All Rapid Influenza Tests
This article was originally published in The Gray Sheet
FDA’s Microbiology Devices Advisory agrees with FDA’s proposals June 13 to move rapid flu antigen tests to class II with new sensitivity and specificity thresholds and post-market standards to address concerns with poor performance.
You may also be interested in...
Updates on flu-assay regulation, an upcoming eye-care panel, and an FDA safety note on implantable infusion pump risks with MRI.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.